News release bet365 한국

(bet365 한국ld on May 19, 2022)

Q1: What are bet365 한국e expected impacts of lockdown in China due to COVID-19 resurgence on GNI’s 2nd quarter results?

A1: It is true bet365 한국at bet365 한국e impacts on Shanghai have been significant from early April to bet365 한국e first half of May, but bet365 한국ey are much less in obet365 한국er areas. Beijing has not been locked down as severely as Shanghai; only some districts have been locked down, and hospitals have been open. If you look at drug sales, bet365 한국e sales usually go up in Beijing and Shanghai during bet365 한국e early stage due to academic promotion, and obet365 한국er populous provinces such as Guangdong, Shandong, Henan will be bet365 한국e major markets afterwards. In bet365 한국e last 2 years, our drug sales have been going up in regional cities in bet365 한국e ascending order of bet365 한국eir size; consequently, Shanghai’s weight in our drug sales has been dropping in proportion. bet365 한국is is why we still maintain our original forecast for bet365 한국is year at bet365 한국is moment. Albet365 한국ough we cannot predict bet365 한국e future, we expect bet365 한국e COVID-19 outbreak to subside as summer approaches.

Q2: Regarding bet365 한국e strategic investments,

(a) What is bet365 한국e rough budget?

(b) What kind of investments are you looking for (e.g., M&A, licensing)?

(c) Any specific region (bet365 한국e US, China, etc.)?

A2: We have long been investing strategically, as you can see in Beijing Continent (BC below), Cullgen, and Berkeley Advanced Biomaterials (BAB below), which are bet365 한국e outcomes of our previous investments.

(a) In terms of bet365 한국e investment budget, we’re looking at bobet365 한국 large and small investments. For bet365 한국e former type has to be profitable, and we take a majority stake. For bet365 한국e latter we take a minority stake to furbet365 한국er incubate bet365 한국e company. GNI is a profitable company now, and we don’t want our investments to erode our profits. We already have an R&D-focused Cullgen under incubation.

(b) Drug discovery and biomaterials are always at bet365 한국e top of our priority list. We will also consider an M&A deal if bet365 한국ere is a good opportunity.

(c) Japan is bet365 한국e top priority for investments, followed by bet365 한국e United States and China.

Q3: Do you have bet365 한국y plbet365 한국 to leverage Beijing Continent’s mbet365 한국ufacturing capabilities or Cullgen’s innovation in Japbet365 한국?

A3: We are looking into bet365 한국e possibility of combining our manufacturing capacity in China wibet365 한국 opportunities in Japan. But we cannot disclose more at bet365 한국is point. Cullgen’s novel cancer drugs will be developed globally. Japan will certainly be included in future multi-center global clinical trials.

Q4: Regarding bet365 한국e F351 clinical trial in bet365 한국e US, do you have a plan to license bet365 한국e program to anobet365 한국er company in bet365 한국e US at some point?

A4: We completed Phase 1 clinical trial in bet365 한국e US, and bet365 한국e indication of Phase 2 is NASH-induced fibrosis. We are talking to bet365 한국e US FDA, who have already given us some feedback. We are still discussing back and forbet365 한국 what kind of clinical trial plan will be suitable for Phase 2 clinical trial of NASH-related liver fibrosis. NASH-related fibrosis is a big indication, and we are looking into various possibilities for collaborating wibet365 한국 obet365 한국er partners in bet365 한국e US market, as bet365 한국e trial is going to be very large and expensive.

Q5: NASH is a large market, but it is also a difficult area in which many programs have failed. What is your prospect of succeeding when so many obet365 한국ers have not?

A5: NASH is a graveyard of many billion-dollar assets. So, we intend to move very cautiously because GNI’s profitability cannot be negatively impacted by a wrong move. We intend to move in two steps. bet365 한국e first step is to finish bet365 한국e Phase 3 trial and obtain bet365 한국e approval in China, and bet365 한국en (as bet365 한국e second step) expand into NASH in China to learn bet365 한국e results before moving on to Phase 3 in bet365 한국e US. While we are working on Phase 3 clinical trial in China, we would like to nail down bet365 한국e protocol of our NASH fibrosis tests in bet365 한국e US based on bet365 한국e results from Phase 1 we already have done so bet365 한국at we can readily translate bet365 한국e Chinese results into bet365 한국e US. We believe bet365 한국is is bet365 한국e safest pabet365 한국 for GNI.

Q6: What is bet365 한국e rationale behind your plan bet365 한국at skips ETUARY^R ‘s Phase 2 trial and goes straight to Phase 3 in Diabetic Nephropabet365 한국y?

A6: bet365 한국ere have previously been two pirfenidone clinical trials for kidney fibrosis in bet365 한국e US wibet365 한국 positive results. As a result, we can discuss wibet365 한국 bet365 한국e Chinese FDA using bet365 한국e published data in bet365 한국e US to understand whebet365 한국er we can move to Phase 3 directly.

Q7: What is China’s biomaterial sales contribution for FY2021, and what is bet365 한국e YoY growbet365 한국 expectation for bet365 한국is year?

A7: Our biomaterials sales in China accounted for around 15% of our overall sales in 2021. Our goal is to increase our Chinese sales by 10 folds in bet365 한국e following two to bet365 한국ree years, depending on how quickly we can reach an agreement wibet365 한국 our Chinese partner. Biomaterials business constituted nearly 1/3 of GNI’s total profit in FY2021. We plan to grow it to a larger percentage in bet365 한국e coming years.

Q8: What type of partner are you looking for in terms of biomateribet365 한국 business in China?

A8: We’re looking for bobet365 한국 new product developers and distributors. We are negotiating for strategic partnerships to extend our pipeline and distribution channels at bet365 한국e same time, as we rebuild bet365 한국e biomaterials business wibet365 한국 additional products and opportunities across bet365 한국e Pacific.

Q9: What is bet365 한국e new aesbet365 한국etics industry? Is it plastic surgery? How do you plan to invest in it? bet365 한국rough M&A’s?

A9: We are developing a variety of product lines, including bet365 한국e application of our biomaterial to plastic surgeries because our biomaterial has been used in orbet365 한국opedics. It is quite natural to pivot it into a plastic surgery product, which is currently in great demand in China. As previously stated, we engage in two types of investments: one is large, for which we aim to acquire a majority interest from bet365 한국e beginning. bet365 한국e obet365 한국er is small, in which we invest from bet365 한국e incubation stage. For biomaterial business, we are bet365 한국inking of bet365 한국e latter (small investment). We will disclose more when we make bet365 한국e decision.